Takeda Pharmaceutical

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Takeda wins FDA approval for the first oral treatment for Eosinophilic esophagitis (EoE) in the US. The market size for EoE is expected to reach $941.8 million by 2031. Takeda's new CFO, Milano Furuta, will focus on growth and increasing shareholder returns.

Takeda Pharmaceutical: Eohilia's FDA Approval Brings Tailwinds

Japan's Takeda Pharmaceutical will scale up production of its dengue vaccine Qdenga through a partnership with Indian vaccines maker Biological E., the companies said on Tuesday.

Japan's Takeda partners with India's Biological E. to boost dengue vaccine production

CAMBRIDGE, Mass. & HYDERABAD, India--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) and Biological E. Limited (BE), a leading India-based Vaccines and Pharmaceutical Company, today announced a strategic partnership to accelerate access to QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003) multi-dose vials (MDVs). These doses will ultimately be made available for procurement by governments in endemic countries by 2030 at the latest to support National Immunization Programs. MDVs off.

Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas

Drugmaker Takeda said on Monday the U.S. Food and Drug Administration has approved its therapy for a type of allergic inflammation of the esophagus, making it the first oral treatment for the condition.

US FDA approves Takeda's therapy for allergic inflammation in esophagus

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved EOHILIA (budesonide oral suspension), the first and only FDA-approved oral therapy for people 11 years and older with eosinophilic esophagitis (EoE).1 It will be available in 2 mg/10 mL convenient, single-dose stick packs by the end of February. EOHILIA is a corticosteroid indicated for 12 weeks of treatment in patients 11 years and older wit.

FDA Approves Takeda's EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE)

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in 2024.

Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024

Takeda Pharmaceutical Company Limited (TAK) Q3 2023 Earnings Call Transcript

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced that Costa Saroukos, chief financial officer, has decided to leave Takeda to return to his home-country of Australia to be closer to family. Mr. Saroukos will step down as CFO, effective April 1, 2024 and will remain with the company as a board director until June 28, 2024. Milano Furuta, president of Takeda's Japan Pharma Business Unit (JPBU), will succeed Mr. Saroukos, effective April 1, 2024. Mr. F.

Takeda Announces Chief Financial Officer Succession

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for the third quarter of fiscal year 2023 (period ended December 31, 2023). With year-to-date strong momentum in its Growth & Launch Products (+12.7% at CER) offsetting the significant revenue impact of generic entrants, Takeda remains on track towards its full-year Management Guidance. Takeda chief financial officer, Costa Saroukos, commented: “In FY2023 Q3 we made further progr.

Takeda Announces Third-Quarter FY2023 Results; On-Track Towards Full-Year Management Guidance With Strong Momentum in Growth & Launch Products

Protagonist Therapeutics

Takeda Will Be Protagonist's Co-Development, U.S. Co-Commercialization Partner With 50:50 Profit Share, and With Exclusive Ex-U.S. Global Rights to Commercialize Rusfertide, Protagonist's Investigational Injectable Hepcidin Mimetic Currently in Development for the Treatment of Polycythemia Vera (PV) Takeda Will Make an Upfront Payment of $300 Million at Closing Partnership Combines Protagonist's Leadership in Pharmaceutical Peptide Drug Development With Takeda's Commercial Expertise and 70-Plus Year Legacy of Driving Innovation Within the Rare Hematology Community Protagonist to Host Conference Call and Webcast Today at 4:30 PM ET OSAKA, JAPAN, CAMBRIDGE, MA, and NEWARK, CA / ACCESSWIRE / January 31, 2024 / Takeda ( TSE:4502/NYSE:TAK ) and Protagonist Therapeutics, Inc., ( Nasdaq:PTGX ) today announced the signing of a worldwide license and collaboration agreement for the development and commercialization of rusfertide, an investigational injectable hepcidin mimetic peptide of the natural hormone hepcidin, currently in a pivotal Phase 3 trial, VERIFY, for the treatment of Polycythemia Vera (PV). PV is a rare chronic blood disorder characterized by excessive production of red blood cells that affects as many as 160,000 patients in the U.S.[i], with a similar prevalence in Europe[ii][iii].

Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--U.S. Food and Drug Administration (FDA) approves GAMMAGARD LIQUID for adults with chronic inflammatory demyelinating polyneuropathy (CIDP).

Takeda's GAMMAGARD LIQUID® Approved by U.S. FDA for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda announced that the EC approved HYQVIA as maintenance therapy in patients of all ages with CIDP after stabilization with IVIG.

Takeda's HYQVIA® Approved by European Commission as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Cognizant Technology Solutions

Cognizant will support Takeda's ambition to modernize technology capabilities   TEANECK, N.J. , Jan. 25, 2024 /PRNewswire/ -- Cognizant (NASDAQ: CTSH) announced today an expanded agreement with Takeda (NYSE: TAK), a global biopharmaceutical company, to support the company's digital transformation strategy by reinforcing and supporting its technology efforts.

Cognizant Helping to Modernize Infrastructure and Application Management as Part of Takeda's Digital Transformation

ResMed

Tempur Sealy International

Google “How important is sleep?” and you get three billion results.

3 Stocks to Buy to Benefit From the Booming Sleep Industry

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda announced that it has received global Top Employer certification for 2024. It is one of just 17 companies that received global recognition.

Takeda Named Global Top Employer for Seventh Consecutive Year

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--U.S. Food and Drug Administration (FDA) approves HYQVIA for adults with chronic inflammatory demyelinating polyneuropathy (CIDP).

U.S. FDA Approves Takeda's HYQVIA® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Takeda Pharmaceutical is one of the top pharma companies in the world. It has a broad mix of products in its portfolio, which can provide investors with some stability.

One Ultra-Cheap High-Yield Dividend Stock to Buy

OSAKA, Japan & CAMBRIDGE, Massachusetts--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that LIVTENCITY® (maribavir) has been approved by the National Medical Products Administration (NMPA) of China for the treatment of adult patients with post-hematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT) cytomegalovirus (CMV) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet.

Takeda Announces China NMPA Approval of LIVTENCITY® (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Refractory to Prior Therapies

HYOGO, Japan--(BUSINESS WIRE)--JCR announced the discontinuation of a collaboration with Takeda to develop gene therapies using AAV combined with the JCR J-Brain Cargo® Technology.

JCR Pharmaceuticals and Takeda Pharmaceuticals Announce Discontinuation of Gene Therapy Collaboration

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--The CHMP has recommended the approval of Takeda's HYQVIA in patients with CIDP as maintenance therapy after stabilization with IVIG.

Takeda Receives Positive CHMP Opinion for HYQVIA® as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) and The New York Academy of Sciences today announced the winners of the 2024 Innovators in Science Award for their excellence in, and commitment to, innovative science that has significantly advanced the field of research in cancer immunology. Each winner receives an unrestricted prize of USD 200,000. The 2024 Senior Scientist winner is Robert D. Schreiber, Ph.D., the Andrew M. and Jane M. Bursky Distinguished Professo.

Takeda and The New York Academy of Sciences Announce 2024 Innovators in Science Award Winners

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that it will present 17 company-sponsored abstracts at the 65th American Society of Hematology (ASH) Annual Meeting being held December 9-12, 2023 in San Diego. Takeda's latest research focuses on improving treatment options for those living with hematologic diseases. Takeda's presentations will include oral abstracts detailing new results from the first randomized, controlled, open-label, crossover Pha.

Takeda to Present Data at 65th American Society of Hematology (ASH) Annual Meeting, Demonstrating Continued Commitment to Patients with Hematologic Diseases

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ADZYNMA (ADAMTS13, recombinant-krhn) for the prophylactic and on-demand treatment of adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP). ADZYNMA is the first and only FDA-approved recombinant ADAMTS13 (rADAMTS13) protein designed to address an unmet medical need in people with cTTP by replacing the deficie.

Takeda's ADZYNMA (ADAMTS13, recombinant-krhn) Approved by U.S. FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

The U.S. Food and Drug Administration on Thursday approved Takeda Pharmaceutical's therapy to treat a rare genetic blood disorder in adult and pediatric patients.

US FDA approves Takeda's blood disorder therapy

Pharmaceutical company Takeda 4502, +0.29% said Wednesday that the U.S. Food and Drug Administration approved Fruzaqla as a treatment for certain patients with colorectal cancer.

News for Takeda Pharmaceutical Stock (TAK)